Abstract:Objective:To explore the effect of astragalus polysaccharide (APS) on fatty acid metabolism and lipid toxicity in diabetic cardiomyopathy.Methods:The 5 weeks old male type 2 diabetes model db/db mice were divided into astragalus polysaccharides group,metformin group and diabetic group,according to the random number table method.Each group had 8 rats,which were given APS 2000 mg/kg,metformin 2000 mg/kg and an equal amount of saline through nasogastric tube for 12 weeks respectively.Eight same-age C57BL/6J mice were set as normal group and fed with the same amount of normal saline.Cardiac function was examined by echocardiography in each group.Bligh-Dyer and ESIMS were used to detect myocardial triglyceride deposition.Micro-positron emission tomography was used to detect myocardial fatty acid uptake and index of oxidative metabolism.Western blot was used to detect the protein expression level of key enzymes involved in the metabolism of fatty acids.Results:(1) The LVEDD and LVESD were increased significantly,while the LV fractional shortening (FS) were decreased significantly in diabetic group compared with those in normal group (all P＜0.05).The above indexes of APS group were significantly improved compared with those of diabetic group (all P＜0.05).There was no significant difference in above indexes between metformin group and diabetic group.(2) Compared with the normal group,the fatty acid uptake rate,the free fatty acid oxidation rate,the triglyceride content and the triglyceride subtypes in diabetic group were significantly increased (all P＜0.05) The above indexes in APS group were significantly lower than those in diabetic group (all P＜0.05).There was no significant difference in above indexes between the metformin group and diabetic group.(3) Compared with normal group,the protein expression levels of PPARα,M-CPT 1 and ACO in myocardium were significantly increased in diabetic group (all P＜0.05).The expression of these proteins was significantly lower in APS group than those in diabetic group (all P＜0.05).There was no significant difference in protein expression between the metformin group and diabetic group.Conclusions:APS can improve fatty acid metabolism in diabetic myocardium,including improving cardiac function,decreasing fatty acid uptake and utilization rate,free fatty acid oxidation rate and triglyceride content in the myocardium of diabetic mice,and controlling the fatty acid metabolism related proteins in the myocardium of diabetic mice at normal levels.

Protective effects of AS-IV on diabetic cardiomyopathy by improving myocardial lipid metabolism in rat models of T2DM

Astragaloside IV protects diabetic cardiomyopathy against inflammation and apoptosis via regulating TLR4/MyD88/NF-κB signaling pathway

Astragaloside IV alleviates myocardial damage induced by type 2 diabetes via improving energy metabolism

Astragaloside IV attenuates myocardial dysfunction in diabetic cardiomyopathy rats through downregulation of CD36‐mediated ferroptosis

Astragaloside IV Ameliorates Myocardial Infarction Induced Apoptosis and Restores Cardiac Function

Astragaloside-IV Protects H9C2(2-1) Cardiomyocytes from High Glucose-Induced Injury Via Mir-34A-mediated Autophagy Pathway.

Astragaloside IV Alleviates Infarction Induced Cardiomyocyte Injury by Improving Mitochondrial Morphology and Function

Astragaloside IV alleviates liver injury in type 2 diabetes due to promotion of AMPK/mTOR‐mediated autophagy

Astragaloside IV inhibits ventricular remodeling and improves fatty acid utilization in rats with chronic heart failure

Astragaloside IV ameliorates diabetic nephropathy by modulating the mitochondrial quality control network

Astragaloside Iv Protects Heart from Ischemia and Reperfusion Injury Via Energy Regulation Mechanisms

Astragaloside IV attenuate MI-induced myocardial fibrosis and cardiac remodeling by inhibiting ROS/caspase-1/GSDMD signaling pathway

Beneficial effects of astragaloside IV against angiotensin II-induced mitochondrial dysfunction in rat vascular smooth muscle cells

Taurine May Prevent Diabetic Rats from Developing Cardiomyopathy Also by Downregulating Angiotensin II Type2 Receptor Expression

A Systematic Review of Astragaloside IV Effects on Animal Models of Diabetes Mellitus and Its Complications

Astragaloside IV Ameliorates Streptozotocin Induced Pancreatic β-Cell Apoptosis and Dysfunction Through SIRT1/P53 and Akt/GSK3β/Nrf2 Signaling Pathways

Mechanism of astragalus polysaccharide therapy in improving myocardial lipid toxicity in db/db diabetic obese mice

Co-treatment of Astragaloside IV with Vitamin D in Diabetic Peripheral Neuropathic Rats: Protective Effects and Potential Mechanisms

Astragaloside IV-targeting miRNA-1 attenuates lipopolysaccharide-induced cardiac dysfunction in rats through inhibition of apoptosis and autophagy

Astragaloside IV supplementation attenuates cognitive impairment by inhibiting neuroinflammation and oxidative stress in type 2 diabetic mice

Protective Effects of Astragaloside IV on Db/db Mice with Diabetic Retinopathy